Stem Cell TV | Video / Media News

Page 2,539«..10 20..2,5382,5392,540 2,541..2,550 2,560..»

BODY of Santa Fe Unveils the BODY Natural Facelift: Innovative Facial Mimics the Effect of a Facelift Using Stem Cell …

Posted: November 18, 2012 at 11:44 am

This custom made, cutting edge spa treatment at the BODY Spa at BODY of Santa Fe allows clients to experience the tightening effects of a facelift without the expense or intrusion of surgery. Using technologies such as cryogenic stem cells, ultrasonic, LED light and

Santa Fe, NM (PRWEB) November 15, 2012

After a careful skin analysis, the BODY Natural Facelift begins with a deep cleansing, utilizing either microdermabrasion or a 100% organic herbal enzyme peel, followed by the application of ECOCERT certified Plant Stem Cells (Naturopathica products) or Cryogenic stem cells developed by the DNA Health Institute utilizing pure bovine origin stem cells (from the first trimester embryonic fluid of organic grass fed cows in France)*. The cells been proven to slow cellular aging and counteract a variety of skin problems leaving skin more hydrated, better nourished, less aged, and more radiant. The Natural Facelift treatment is applied with either the plant based products from Naturopathica or DNA Health Institute products.

BODY of Santa Fes highly trained therapists then custom design a blend of cutting edge, non-invasive therapies to amplify collagen and microcurrent to tighten skin and firm and tone facial muscles. LED light is then used to stimulate collagen and correct skin damage followed by ultrasonic therapy to deeply hydrate. Skin is left glowing and healthy with noticeable results after only one treatment.

I created the BODY Natural Face Lift to give our clients an alternative to plastic surgery, said BODY owner Lorin Parrish. As time passes, every cell loses strength and becomes more independent as its surrounding tissue deteriorates and runs slower and rougher. Cells need other cells for information, support, nourishment and direction; for skin to work the way it does, every cell must work in perfect unison with its surrounding tissue.

The BODY Natural Facelift is appropriate for all skin types and skin tones and is available for body treatment areas including the derriere, thighs, stomach, underarms, and chest. The BODY Natural Facelift is $175 for a 90-minute session and a series of 10 sessions is available for $1495. For more information about the Natural Facelift or to make spa reservations, please visit http://www.bodyofsantafe.com or call (505) 986-0362.

*The humane process of extracting bovine embryonic fluidrich in nutrients and stem cellshappens during carefully calculated specific timeline (within the first trimester of the bovines pregnancy) to achieve maximum amounts of stem cells, which have not become specific to the bovine composition, but contain the DNA information to influence and support human skin.

For press inquiries, contact:

Jennifer Hinsley

JLH Media

Posted in Stem Cells | Comments Off

Call for Nominations: “Stem Cell Person of the Year” – Video

Posted: November 18, 2012 at 11:44 am

Call for Nominations: "Stem Cell Person of the Year"
UC Davis stem cell scientist Paul Knoepfler is seeking nominees for the 2012 "Stem Cell Person of the Year." He created the new award to recognize an individual who has made an outstanding difference in the field of stem cell-based cellular and regenerative medicine. Nominees can be scientists, patient advocates, individuals from industry or just about anyone who has made the stem cell field better. The award includes a $1000 cash prize.From:UCDavisHealthViews:60 2ratingsTime:01:48More inScience Technology

Continued here:
Call for Nominations: "Stem Cell Person of the Year" - Video

Posted in Regenerative Medicine | Comments Off

Bernard Siegel – Aging: The Disease, The Cure, The Implications – Video

Posted: November 18, 2012 at 11:44 am

Bernard Siegel - Aging: The Disease, The Cure, The Implications
Bernard Siegel is the full-time Executive Director of the nonprofit Genetics Policy Institute (GPI) based in Palm Beach Gardens, Florida. He received his undergraduate and law degrees from the University of Miami (BA 1972, JD 1975). He is a member of the Florida Bar since 1975. In 2002, Mr. Siegel filed the landmark case seeking a guardian for the alleged clone, "Baby Eve." The case was widely credited for exposing Clonaid , the so-called "human cloning company" as a sham. In 2003, he traded his 30-year courtroom career to found GPI, which leads the global cause in support of stem cell research. He is a recognized policy expert relating to stem cell research, regenerative medicine and cloning. Working with the world #39;s leading stem cell researchers, Mr. Siegel played a pivotal role in protecting the research in the United Nations, which was under the threat of being banned by world treaty. He also works with grassroots activists throughout the United States, educating lawmakers and formulating effective strategies supporting research for cures. Mr. Siegel serves on the board of directors of Americans for Cures and on the advisory boards of the Sabrina Cohen Foundation for Stem Cell Research, The Brooke Ellison Project and Genomics Education Institute. He is a member of the American Society for Bioethics + Humanities. He is a member of the International Society for Stem Cell Research and serves as the co-chair of the ISSCR Governmental Affairs Committee. Mr. Siegel has been ...From:Jeriaska JeriaskaViews:0 0ratingsTime:18:57More inEducation

Posted in Regenerative Medicine | Comments Off

Technological Advances and Favorable Demographics Drives the Regenerative Medicine Market, According to New Report by …

Posted: November 18, 2012 at 11:44 am

GIA announces the release of a comprehensive global report on Regenerative Medicine markets. Global market for Regenerative Medicine is projected to exceed US$4.4 billion by 2018, driven by technological advances and favorable demographics. Potentially huge savings on the medical care front and enhanced healing capabilities of regenerative medicine are expected to be the major contributing factors for market growth. Supportive political actions, Government funding, corporate investment, clinical outcomes, increased awareness, increased endorsement from doctors, enhanced manufacturing technologies, and novel sources of stem cells are also expected to impart momentum to the growth of Regenerative Medicine.

San Jose, California (PRWEB) November 16, 2012

Though the current market for regenerative medicine is small in size, the market for tissue engineering holds the potential to reach enormous levels in the coming decade. Growth in the regenerative medicine market is forecast to be propelled by new products to be introduced in the segments of orthopedics, neurology, organ regeneration, wound care, cardiovascular, and urology. With the strengthening of existing markets, the regenerative medicine market is also expected to witness penetration in other markets including Japan, Europe and other emerging countries.

Regenerative Medicine market is presently witnessing the introduction of a limited number of regenerative therapies targeting mainly orthopedics (including bone and joint applications), wound care, and body sculpture. There are a number of therapies in the development pipeline addressing potential areas such as Cardiovascular, Nerve repair, Diabetes and Inflammatory diseases among others. In addition, the future is also expected to witness the introduction of laboratory grown tissue engineered organs and tissues. However, the development of fully functional organs is expected to be very complex and the prediction of the success of this attempt is impossible at present. As an alternative to this approach, attempts to develop the organ in parts are also going on which is relatively less complicated and offer higher success rates.

Orthopedics segment which includes spine, bone grafts and bone substitutes is the largest among the different fields of global regenerative medicine market. Advancements in the biological science has drastically revolutionized regenerative medicine domain. Specifically, regenerative medicine in bone and joint applications made huge strides over the past few years. Healthy growth in the bone and joint applications is primarily due to the ageing baby boomer population and escalating incidence of osteoporosis, arthritis, and several other bone and joint traumas, including knee injuries and hip fractures. Growing awareness among people for regenerative medicines and increasing usage of non-autograft products by doctors and medical personnel are also stimulating growth for these products.

As stated by the new market research report on Regenerative Medicine, the US represents the largest market worldwide. Though the US is expected to retain its leading position, growth in other markets such as Japan is forecast to be higher than that of the US. The higher growth expected in the other markets is attributed to the level of Government as well as public support for the Regenerative Medicine sector. Though the US spends a substantial amount in the area of research, other Governments are also increasing their support for the sector. Bone Replacements represents the largest application for Regenerative Medicine in Bone and Joint Applications, while Tissue Replacements represents the application with highest potential for growth.

The global regenerative medicine market consists of companies engaged in harvesting, processing, purification, cryopreservation, storage, administration, or research activities of cells and tissue-based products. Major players in the global marketplace include BioVest International Inc., Curis Inc., Cytori Therapeutics Inc., Evotec AG, Forticell Bioscience Inc., Geron Corporation, Integra LifeSciences Corporation, LifeCell Corporation, Osiris Therapeutics Inc., Tengion Inc., Tepha Inc., and TiGenix N.V.

The research report titled "Regenerative Medicine: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, regulatory scenario, company profiles, mergers, acquisitions, and other strategic industry activities. The report provides market estimates and projections for Regenerative Medicine Products for Bone and Joint Applications (in US$) by Bone Replacements, Bone Stimulators, and Tissue Replacements applications. Geographic markets analyzed include the United States, Europe and Rest of World.

For more details about this comprehensive market research report, please visit

http://www.strategyr.com/Regenerative_Medicine_Market_Report.asp

Go here to read the rest:
Technological Advances and Favorable Demographics Drives the Regenerative Medicine Market, According to New Report by ...

Posted in Regenerative Medicine | Comments Off

Genetic Engineering Of Mesenchymal Stem Cells – Video

Posted: November 18, 2012 at 11:43 am

Genetic Engineering Of Mesenchymal Stem Cells
ll4.me Genetic Engineering Of Mesenchymal Stem Cells 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. Meyerrose, I. Rosova, m. Dao, P. Herrbrich, G. Bauer, JA Nolta- 3. Gene Expression Profiles of Mesenchymal Stem Cells; DG Phinney- 4. In Vivo Homing and Regeneration of freshly isolated and culture Murine Mesenchymal Stem Cells; RE Ploemacher- 5. Non-human primate models of Mesenchymal Stem Cell Transplantation; SM Devine, R. Hoffman- 6. Engineering of Human Adipose-derived Mesenchymal Stem-like Cells; JK Fraser, M. Zhu, B. Strem, MH Hedrick- 7. Uncommitted Progenitors in Cultures of Bone Marrow-derived Mesenchymal Stem Cells; JJ Minguell, A. Rices, WD Sierralta- 8. Bone Marrow Mesenchymal Stem Cell Transplantation for Children with severe Osteogenesis Imperfecta; EM Horwitz, PL Gordon- 9. Clinical Trials of Human Mesenchymal Stem Cells to support Hematopoietic Stem Cell Transplantation; ON Ko EAN/ISBN : 9781402039591 Publisher(s): Springer Netherlands Discussed keywords: Stammzelle Format: ePub/PDF Author(s): Nolta, Jan A. 1. Mesenchymal Stem Cell Engineering and Transplantation: An introduction; F. Aerts, G. Wagemaker- 2. Establishment and Transduction of primary human Stromal/Mesenchymal Stem Cell Monolayers; T. MeyerFrom:jonibishop696Views:0 0ratingsTime:00:12More inPeople Blogs

Original post:
Genetic Engineering Of Mesenchymal Stem Cells - Video

Posted in Genetic Engineering | Comments Off

Is the detection of early markers of Epstein Barr virus of diagnostic value?

Posted: November 18, 2012 at 11:42 am

Public release date: 16-Nov-2012 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 x2156 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, November 15, 2012Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and a risk for serious disease in liver transplant recipients. Molecular tests that can identify early protein markers produced by EBV may have value for diagnosing active infection. The benefits of this diagnostic approach in patients with mononucleosis and in EBV-infected transplant patients are evaluated in an article published in BioResearch Open Access, a bimonthly peer-reviewed open access journal from Mary Ann Liebert, Inc., publishers. The article is available free on the BioResearch Open Access website.

Andrea Crowley, Jeff Connell, Kirsten Schaffer, William Halla, and Jaythoon Hassan, University College Dublin and St. Vincent's University Hospital, Dublin, Ireland, compared three immunoassay methods for detecting antibodies produced by the body in response to EBV infection and the presence of proteins that comprise the EBV early antigen complex. The researchers determined which of the diagnostic tests could better predict EBV infection in patients with mononucleosis or in immunosuppressed adult liver transplant recipients. The article "Is There Diagnostic Value in Detection of Immunoglobulin G Antibodies to the EpsteinBarr Virus Early Antigen?" presents the complete methodology and results of this study.

"Having the ability to predict the risk of developing EBV-induced lymphoproliferative disorders after a transplant has important consequences for patient care, as it would allow for prompt therapy and could potentially decrease patient mortality," says Editor-in-Chief Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal that provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMedCentral. All journal content is available on the BioResearch Open Access website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, Human Gene Therapy and HGT Methods, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

See original here:
Is the detection of early markers of Epstein Barr virus of diagnostic value?

Posted in Genetic Engineering | Comments Off

Research and Markets: Research Report on the Biotechnology Market in India 2012

Posted: November 18, 2012 at 11:41 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dvn5gf/biotechnology) has announced the addition of the "Biotechnology Market in India" report to their offering.

The Indian biotechnology industry has been growing substantially in the last couple of years. Biotech companies have grown in the country exponentially as a liberalized intellectual property regime and skilled workforce along with low manufacturing costs have boosted the growth of the industry.

With the industry not facing much of the brunt from the global economic recession, the Indian biotechnology industry has been gathering investment and is benefitting from the cost cutting efforts ongoing in many developed countries.

With the diverse flora and fauna that India has, along with the large gene pool and ideal climate, the biotechnology market in India is progressing well, supported by favorable regulations by the Government of India.

Taiyou Research analyzes the potential of the Indian Biotechnology Industry in its research report Biotechnology market in India.

The report covers the following:

- A complete coverage of the global biotechnology market including industry definition, market profile, market statistics, industry performance, market segmentation, competition in the industry, global financing for biotechnology, and a future perspective.

- Moving to the analysis of the biotechnology market in India, we analyze the industry through a market profile, impact of the economic recession on the market, investment in the industry, and biotech companies in India.

- Major tie-ups in the recent years are looked at, along with the issue of Bt Brinjal that rocked the industry recently. The growth of stem cell research and biosimilars is analyzed.

Excerpt from:
Research and Markets: Research Report on the Biotechnology Market in India 2012

Posted in Biotechnology | Comments Off

Mrs. Linda Flournoy – Video

Posted: November 18, 2012 at 11:40 am

Mrs. Linda Flournoy
describes ger experience with Stem Cell Therapy PRPFrom:FLRegenerativeMedViews:2 0ratingsTime:02:27More inEducation

Go here to read the rest:
Mrs. Linda Flournoy - Video

Posted in Cell Therapy | Comments Off

Video 7 – November 14, 2012 – Adult Stem Cells Progress.wmv – Video

Posted: November 18, 2012 at 11:40 am

Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv
Breif interview of my progress with Multiple Sclerosis with Adult Stem Cell therapy after my experience with Tysabri, Gilenya and Ampira failed.From:MSajourneyfromwithinViews:1 0ratingsTime:04:21More inEducation

Read more from the original source:
Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off

Cultivator of Brain Parts

Posted: November 18, 2012 at 8:00 am

Yoshiki Sasai is not just an ordinary tissue engineer who tries to coax stem cells to grow into fully formed bodily structures. It is true that Sasai has made his mark by taking on big projects like using stem cells to whip up a retina, cortical tissue and the cerebellum, involved with balance and movement. But his research has gone deeper by delving into the way stem cells organize themselves into complex structures under the influence of genes and the prenatal environment. Read a profile of Sasai here to accompany “ Grow Your Own Eye ,” Sasai’s own account of growing a retina in the November Scientific American .

[More]

Source:
http://rss.sciam.com/click.phdo?i=7291cadd43ac0cf30e9687431d559702